Mitomycin pyelocalyceal (Jelmyto)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. Formulated for pyelocalyceal infusion.

Diseases for which it is used

History of changes in FDA indication

  • 2020-04-15: Approved for adult patients with low-grade upper tract urothelial cancer (LG-UTUC). (Based on OLYMPUS)

Also known as

  • Brand name: Jelmyto